$SCNX News

Scienture Eric Sherb Resigns As CFO Effective May 26, 2026; Narasimhan Mani Appointed As Interim CFO Effective May 26, 2026

Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY

SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor

USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"

Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing

Scienture Holdings shares are trading higher after the company announced it has been granted 180-day extension by the Nasdaq to regain compliance.

Scienture Holdings shares are trading higher after the company announced it has been granted 180-day extension by the Nasdaq to regain compliance.

SCIENTURE HOLDINGS Gets 180‑Day Nasdaq Extension; Compliance Deadline Now October 12

Scienture Holdings shares are trading lower. The company reported FY25 financial results.

EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025

Scienture FY25 Revenue $431.6K Vs $136.6K YoY; Net Loss Per Common Share $(2.70) Vs $(5.41) YoY

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Scienture Holdings shares are trading higher after the company formalized multiple commercial Group Purchasing Organization to increase the availability of its Rezenopy naloxone spray to reverse opioid overdose.

EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market

EXCLUSIVE: Scienture Expands Institutional Footprint Through GPO Agreements For REZENOPY

Maxim Group Initiates Coverage On Scienture Holdings with Buy Rating, Announces Price Target of $1.5

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

SCIENTURE HOLDINGS Reaffirms Plan To Commercially Roll Out REZENOPY In Q2

Scienture Expands Access to ARBLI and Prepares for Launch of REZENOPY in 2026

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment